Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to evaluate 6MW5311 for hematologic malignancies, specifically Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma (MM)

Next Previous
Trial Profile

A clinical study to evaluate 6MW5311 for hematologic malignancies, specifically Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma (MM)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 6MW 5311 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Multiple myeloma
  • Focus Therapeutic Use

Most Recent Events

  • 12 Jun 2026 According to Mabwell (Shanghai) Bioscience media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its clinical trial application for its innovative LILRB4/CD3 targeting T Cell Engager (TCE) bispecific antibody (R&D code: 6MW5311), for the treatment of hematologic malignancies (acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma).
  • 21 Apr 2026 New trial record
  • 16 Apr 2026 According to Mabwell (Shanghai) Bioscience media release, the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top